ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipple Aspirate Fluid

NCT ID: NCT02218385

Last Updated: 2016-10-19

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 52 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-08-31
• Study Completion Date: 2014-08-31

Brief Summary

The purpose of this study is to measure the performance characteristics for the collection, fixation and transportation of clinical nipple aspirate fluid (NAF) specimens of the ForeCYTE Breast Aspirator across 3 independent labs and the National Reference Laboratory for Breast Health (NRLBH). The study hypothesis is that each lab will have a specimen acceptability rate of at least 90%. If it is assumed that the true level of acceptability testing is approximately 96%, then the lower bound of a one-sided 95% confidence interval is expected to be at least 90%.

Detailed Description

A) NAF Collection at physician's office: The Principle Investigator identified and qualified the study subjects. He and the assigned study coordinator from his clinic completed all entries in the Study Case Report Form related to the collection site. He collected the NAF specimens at the Physician Office Collection Sites in accordance with the Instructions for Use.

B) NAF Processing at physician's office: The Principle Investigator's designate processed the NAF specimens for shipment to the selected laboratories in accordance with the Instructions for Use.

C) NAF Transport from physician's office to laboratory: The patient specimen collection membranes were placed in resealable pouches, packed in shipping boxes (provided) and transported by Federal Express to the participating Independent Clinical Laboratories. The Federal Express packaging was pre-labeled for the PI within each of the four laboratories and the specimens were sent in the order in which they were collected to each of the laboratories. Left and right breast specimen from the same subject were sent to the same lab, but in a subject based sequence. The shipments will be shipped serially to lab ABCD, ABCD, ABCD, ABCD, etc. So specimens from subject 1 went to laboratory A, specimens from subject 2 to lab B, specimens from subject 3 to lab C, specimens from subject 4 to lab D, specimens from subject 5 to lab A, etc. The PI completed the Testing Facility Shipping and Receiving Tracking Form for all specimens.

D) NAF Processing at laboratory: The NAF was processed at the clinical cytology laboratories in accordance with the Instructions for Use that accompanied each patient kit.

E) NAF Cytology Classification: A trained, board-certified pathologist read the slides. The data was reported in the Case Report Form according to the format recommended by the College of American Pathologists. The criteria for reading and interpreting the slides are contained in Table 2 and were adapted from King, et al. The laboratory portion of the Case Report Form was completed for each patient.

Conditions

Breast Neoplasms

Study Design

• Study Time Perspective: PROSPECTIVE

Study Groups

ForeCYTE Breast Aspirator

ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing

ForeCYTE Breast Aspirator

Intervention Type: DEVICE

ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing

Interventions

ForeCYTE Breast Aspirator

ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Healthy, female, age 20-75 years, from whom bi-lateral specimens can be obtained.

2. Any woman for whom NAF cytology testing is considered to be beneficial by her physician.

3. Non-lactating and non-pregnant (as documented by date of Last Menstrual Period or post-menopausal).

4. Good general health as determined by medical history, breast disease/cancer history, and clinical breast exam.

5. Willing to give informed consent and follow study procedures as directed.

Exclusion Criteria

1. Medical condition/psychiatric conditions making subjects a poor candidate for study, as determined by the Principal Investigator.

2. Pregnancy or suspicion of pregnancy.

3. Open cutaneous wounds or atopic dermatitis in the area of the nipple-areolar complex.

4. No or inverted nipple on the breast unfit for fluid collection, or significant prior surgery in the area of the nipple-areolar complex.

5. Participation in an investigational drug or device study less than 30 days prior to enrollment in this study.

6. Pregnancy, childbirth, or lactation less than 90 days prior to enrollment in this study.

7. Acute illness, including taking antibiotics, analgesics, antipyretics and/or cold medications less than 7 days prior to enrollment in this study.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Quest Diagnostics-Nichols Insitute

INDUSTRY

Sponsor Role: collaborator

National Reference Laboratory for Breast Health

UNKNOWN

Sponsor Role: collaborator

Sound Pathology Associates

UNKNOWN

Sponsor Role: collaborator

Puget Sound Institute of Pathology

OTHER

Sponsor Role: collaborator

Atossa Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jonathan D. Herman, MD, FACOG

Role: PRINCIPAL_INVESTIGATOR

Elite Women's Health

Locations

Elite Women's Health

New Hyde Park, New York, United States

Countries

United States

Other Identifiers

GCP003

Identifier Type: -

Identifier Source: org_study_id